| Code | CSB-RA023986MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Denosumab, targeting TNFSF11 (Tumor Necrosis Factor Superfamily Member 11), also known as RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand). TNFSF11 is a critical cytokine that regulates osteoclast differentiation, activation, and survival, playing a central role in bone remodeling and calcium metabolism. By binding to its receptor RANK on osteoclast precursors, TNFSF11 promotes bone resorption, making it a key therapeutic target in osteoporosis, bone metastases, and skeletal-related malignancies. Dysregulation of the RANKL pathway is implicated in various pathological conditions including postmenopausal osteoporosis, rheumatoid arthritis, and cancer-induced bone disease.
Denosumab, the reference antibody, is a fully humanized IgG2 monoclonal antibody that inhibits RANKL-RANK interaction, thereby preventing osteoclast-mediated bone destruction. This biosimilar provides researchers with a valuable tool for investigating bone metabolism, osteoclastogenesis, tumor-bone interactions, and skeletal disease mechanisms in preclinical models. It supports studies examining RANKL signaling pathways and the development of therapeutic strategies for bone-related disorders.
There are currently no reviews for this product.